Min Zhang1, Guo-Jun Zhao2, Kai Yin1, Xiao-Dan Xia1, Duo Gong1, Zhen-Wang Zhao1, Ling-Yan Chen1, Xi-Long Zheng3,4, Xiao-Er Tang5, Chao-Ke Tang1. 1. Institute of Cardiovascular Disease, Key Lab for Atherosclerology of Hunan Province, Medicine Research Center, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China. 2. Department of Histology and Embryology, Guilin Medical University. 3. Department of Biochemistry and Molecular Biology, The Libin Cardiovascular Institute of Alberta, The University of Calgary, Health Sciences Center. 4. Key Laboratory of Molecular Targets & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University. 5. Department of Pathophysiology, Shaoyang University.
Abstract
BACKGROUND: It has previously been demonstrated that apolipoprotein A-1 (apoA-1) binding protein (AIBP) promotes apoA-1 binding to ATP-binding cassette transporter A1 (ABCA1) and prevents ABCA1 protein degradation so as to inhibit foam cell formation. Because apoA-1 inhibits inflammatory signaling pathways, whether AIBP has an inhibitory effect on inflammatory signaling pathways in THP-1-derived macrophages is investigated.Methods and Results: Analysis of inflammation-related gene expression indicated that AIBP decreased lipopolysaccharide (LPS)-mediated macrophage inflammation. AIBP significantly prevented NF-κB nuclear translocation. Further, AIBP prevented the activation of mitogen-activated protein kinases (MAPKs), including p38 MAPK, extracellular-signal regulated kinase and c-Jun N-terminal kinase. AIBP decreased MyD88 expression at both mRNA and protein levels, but did not have any effect on TLR4 expression. Moreover, treatment with both AIBP and apoA-1 decreased the abundance of TLR4 in the lipid raft fraction. AIBP lacking 115-123 amino acids (∆115-123), however, did not have such effects as described for intact AIBP. In addition, knockdown of ABCA1 inhibited the effects of AIBP on inflammatory factor secretion. CONCLUSIONS: These results suggest that AIBP inhibits inflammatory signaling pathways through binding to apoA-1 and stabilizing ABCA1, and subsequent alteration of lipid rafts and TLR4 in the cell membrane.
BACKGROUND: It has previously been demonstrated that apolipoprotein A-1 (apoA-1) binding protein (AIBP) promotes apoA-1 binding to ATP-binding cassette transporter A1 (ABCA1) and prevents ABCA1 protein degradation so as to inhibit foam cell formation. Because apoA-1 inhibits inflammatory signaling pathways, whether AIBP has an inhibitory effect on inflammatory signaling pathways in THP-1-derived macrophages is investigated.Methods and Results: Analysis of inflammation-related gene expression indicated that AIBP decreased lipopolysaccharide (LPS)-mediated macrophage inflammation. AIBP significantly prevented NF-κB nuclear translocation. Further, AIBP prevented the activation of mitogen-activated protein kinases (MAPKs), including p38 MAPK, extracellular-signal regulated kinase and c-Jun N-terminal kinase. AIBP decreased MyD88 expression at both mRNA and protein levels, but did not have any effect on TLR4 expression. Moreover, treatment with both AIBP and apoA-1 decreased the abundance of TLR4 in the lipid raft fraction. AIBP lacking 115-123 amino acids (∆115-123), however, did not have such effects as described for intact AIBP. In addition, knockdown of ABCA1 inhibited the effects of AIBP on inflammatory factor secretion. CONCLUSIONS: These results suggest that AIBP inhibits inflammatory signaling pathways through binding to apoA-1 and stabilizing ABCA1, and subsequent alteration of lipid rafts and TLR4 in the cell membrane.
Authors: Soo-Ho Choi; Aaron M Wallace; Dina A Schneider; Elianne Burg; Jungsu Kim; Elena Alekseeva; Niki Dj Ubags; Carlyne D Cool; Longhou Fang; Benjamin T Suratt; Yury I Miller Journal: JCI Insight Date: 2018-08-23
Authors: Juliana M Navia-Pelaez; Soo-Ho Choi; Luciano Dos Santos Aggum Capettini; Yining Xia; Ayelet Gonen; Colin Agatisa-Boyle; Lauriane Delay; Gilson Gonçalves Dos Santos; Glaucilene F Catroli; Jungsu Kim; Jenny W Lu; Benjamin Saylor; Holger Winkels; Christopher P Durant; Yanal Ghosheh; Graham Beaton; Klaus Ley; Irina Kufareva; Maripat Corr; Tony L Yaksh; Yury I Miller Journal: J Exp Med Date: 2021-05-10 Impact factor: 14.307